New platform combines AI-assisted evidence workflows, advanced quantitative analysis and Cytel expertise to help life sciences teams move faster from research question to decision-ready evidence.

Cambridge, MA – November 2, 2026 – Cytel Inc., a global leader in statistical software and advanced quantitative solutions for the life sciences industry, today announced the launch of the Estimed™ software platform, a connected evidence synthesis platform designed to help life sciences organizations accelerate how evidence is identified, synthesized, analyzed and applied to strategic decision-making.

Life sciences teams are navigating rapidly growing volumes of scientific and clinical evidence while facing increasing pressure to generate robust, transparent insights within shorter timelines. Yet evidence generation often remains fragmented across literature databases, screening tools, spreadsheets, statistical software, and reporting workflows, creating manual handoffs, duplicated effort and challenges in maintaining and reusing evidence.

Estimed brings AI-assisted evidence workflows and advanced quantitative analysis into a connected environment, helping teams reduce repetitive work while maintaining scientific and methodological oversight. By connecting evidence identification and synthesis with advanced analysis, including network meta-analysis (NMA), Estimed helps teams move more efficiently from research question to decision-ready evidence.

“The challenge evidence teams are facing isn’t simply finding more information; it’s turning an increasingly complex evidence base into reliable insights quickly enough to inform important decisions,” said Kevin Trimm, Chief Product Officer at Cytel. “With Estimed, we’re connecting AI-assisted evidence workflows with the advanced quantitative methods Cytel is known for. Our goal is not to automate scientific judgment, but to give evidence experts better technology to work faster, connect evidence with analysis, and focus their attention where it creates the greatest value.”

Technology and Expertise, Together

Estimed powers Cytel’s consultant-led Evidence, Value and Access (EVA) solutions while also being available for direct use by clients’ internal evidence teams. This dual approach gives life sciences organizations flexibility in how they generate evidence, whether leveraging Cytel’s scientific expertise, building internal capabilities, or combining both. From targeted and systematic literature reviews to landscape assessments and network meta-analysis, Estimed brings together connected technology and Cytel’s methodological, analytical, and strategic expertise to support evidence needs across the product lifecycle.

“Technology can fundamentally change how quickly we generate and interrogate evidence alongside humans-in-the-loop, but it does not remove the need for rigorous methodology, scientific interpretation, and strategic thinking,” said Ben Rousseau, Vice President EVA Market Access at Cytel. “Estimed brings those elements together, giving customers flexibility in how they build their evidence capabilities, whether it be Targeted Literature Reviews, Systematic Literature Reviews, NMAs or other HEOR and market access activities, while keeping scientific expertise at the center.”

Estimed at ISPOR Europe 2026

Cytel will showcase Estimed at ISPOR Europe 2026 at Booth 1315, where attendees can see the platform in action, including its evidence workflow and NMA capabilities, and discuss how Estimed can support internal evidence teams, Cytel consultant-delivered evidence programs, or hybrid approaches.

Cytel will also work with select organizations on Estimed pilots as the platform continues to expand, providing opportunities to evaluate the technology against real-world evidence-generation needs and inform future development.

For more information about Estimed or to request a demonstration, visit our website.

About Cytel

Cytel is the world’s leading provider of statistical software, advanced quantitative solutions, and statistical methods for the life sciences industry, committed to advancing human health. For nearly four decades, Cytel has helped biopharmaceutical organizations design, execute, and optimize clinical development programs through innovative software, scientific expertise, and data-driven decision-making.

Across clinical development, real-world evidence, evidence synthesis, market access and advanced analytics, Cytel combines technology with deep scientific and methodological expertise to help organizations make better-informed decisions throughout the product lifecycle.

Estimed™ is a trademark of Cytel Inc. All rights reserved.

Media Contact

Sofie Vandevyver
VP, Global Head of Marketing
sofie.vandevyver@cytel.com

Share Via